Skip to main content
Home

Search


NEI on Social Media | Search A-Z | en español | Text size S M L
  • About NEI
    • NEI Research Accomplishments
    • Budget and Congress
    • About the NEI Director
    • History of the NEI
    • NEI 50th Anniversary
    • NEI Women Scientists Advisory Committee (WSAC)
    • Board of Scientific Counselors
    • National Advisory Eye Council (NAEC)
    • Donating to the NEI

    Menu About NEI Block

     Contact Us

     Visiting the NIH Campus

    Mission Statement

    As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.”

  • News & Events
    • Events Calendar
    • NEI Press Releases
    • News from NEI Grantees
    • Spokesperson bios
    • Statistics and Data
    • Resources for the media

    Pressroom Contacts

    Dustin Hays - Chief, Science Communication
    dustin.hays@nih.gov

    Kathryn DeMott, Media Relations
    Kathryn.DeMott@nih.gov

    NEI Office of Communications
    (301)496-5248

  • Health Information
    • Frequently asked questions
    • Clinical Studies
    • Spanish Language Information
    • Publications Catalog
    • Photos and Images
  • Grants and Funding
    • Extramural Research
    • Division of Extramural Science Programs
    • Division of Extramural Activities

    Extramural Contacts

    National Eye Institute
    Division of Extramural Research
    6700B Rockledge Dr., MSC 6914
    Bethesda, MD 20892
    (FedEx, UPS, and other courier services use: Bethesda MD 20817)
    301-451-2020

  • Research at NEI
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Laboratories, Sections and Units
    • eyeGENE
    • Division of Epidemiology and Clinical Applications

    Office of the Scientific Director

    Sheldon S. Miller, Ph.D., Scientific Director
    David M. Schneeweis, Ph.D., Deputy Scientific Director

    Office of the Clinical Director

    Brian P. Brooks, M.D, Ph.D., Clinical Director
    Emily Y. Chew, M.D., Deputy Clinical Director

  • Education Programs
    • National Eye Health Education Program (NEHEP)
    • Diabetic Eye Disease Education Program
    • Glaucoma Education Program
    • Low Vision Education Program
    • Hispanic/Latino Program
    • Vision and Aging Program
    • African American Program
  • Training and Jobs
    • Jobs
    • NEI Summer Intern Program
    • Diversity In Vision Research & Ophthalmology (DIVRO)
    • Student Training Programs

    To search for current job openings visit HHS USAJobs

Home » News » Pressreleases » Treatment for Retinitis Pigmentosa Reported
Listen

Topics

Age-Related Macular Degeneration (AMD)
AIDS-related eye disease (cytomegalovirus [CMV] retinitis)
Amblyopia
Anophthalmia and Microphthalmia
Appointments
Astigmatism
Audacious Goals Challenge
Awards
Behçet’s Disease of the Eye
Bietti's Crystalline Dystrophy
Blepharitis
Blepharospasm
Cataracts
Clinical Studies
coloboma
Color Blindness
Convergence Insufficiency (CI)
Cornea
Diabetic Eye Disease
Dry Eye
Education Programs
Eye Cancer
Eye Surgery
Floaters
Gene
Glaucoma
Healthy Vision Month
Hispanic/Latino Americans
Histoplasmosis
Hyperopia
Idiopathic Intracranial Hypertension
Infancy
Infectious Eye Disease
Leber Congenital Amaurosis (LCA)
Low Vision
Macular Degeneration
Macular Edema
Macular Hole
Macular Pucker
Myopia
NEI
NEI Remembers
NEI Website
Optic Nerve Disorders
Pink Eye (Conjunctivitis)
Preschool
Rare Diseases
Refractive Errors
Refractive Surgery
Retina
Retinal Disease
Retinitis Pigmentosa
Retinoblastoma
Retinopathy of Prematurity (ROP)
Retinoschisis
Spanish
Spanish
Stargardt Disease
Stem Cells
Usher Syndrome
Uveitis/Inflammatory Eye Disease
Vision Screening
World Sight Day

Treatment for Retinitis Pigmentosa Reported

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

06/14/93

Most adults with blinding retinitis pigmentosa (RP) should take adaily, 15,000 IU vitamin A supplement, based on results from a large,randomized clinical trial published today in the Archives ofOphthalmology.

This recommendation is the first from a well-designed clinical trialindicating that people can be treated for this retinal disease. “Thisis exciting news,” said Carl Kupfer, M.D., director of theNational Eye Institute, which supported the six-year study. “Whilevitamin A supplementation certainly does not represent a cure, it doessignify a first step in managing these diseases.”

Eliot L. Berson, M.D., the study’s principal investigator andProfessor of Ophthalmology at Harvard Medical School, said that adultswho supplemented their diets with 15,000 IU of vitamin A daily had onaverage about a 20 percent slower annual decline of remaining retinalfunction than those not taking this dose.

Based on this finding, Dr. Berson and his colleagues estimated thatan average patient in the study who started taking a 15,000 IU vitaminA capsule at age 32 would retain some useful vision until age 70,whereas a patient not on this dose would lose useful vision at age 63.

The investigators also recommended that adults with RP should avoidtaking high-dose vitamin E supplements. In the study, the diseaseappeared to progress faster on average in patients on a daily, 400 IUvitamin E supplement than in those taking a trace amount of thevitamin. Dr. Berson said that the study showed no evidence that normaldietary or small supplemental amounts of vitamin E have an adverseeffect on the disease.

Retinitis pigmentosa is a group of inherited retinal diseases thataffects about 100,000 Americans and 1.5 million people worldwide. Itcauses the progressive deterioration of specialized, light-absorbingcells in the retina, the paper-thin tissue that lines the back of theeye like film in a camera.

As these cells slowly degenerate, people with RP develop nightblindness and a gradual loss of peripheral vision. By about age 40,most have tunnel vision, although many may retain good central vision.Between the ages of 50 and 80, however, they typically lose theirremaining sight. The extent of vision loss in people of the same agewith RP may be different.

Dr. Berson stressed that adults considering vitamin Asupplementation should first:

  • Consult with their eye care professional about vitamin Asupplementation.
  • Have their blood level of vitamin A measured before startingtreatment. If people have pre-existing liver disease or abnormallyhigh blood levels of vitamin A, they will need to adjust theirvitamin A intake.
  • Take vitamin A palmitate, as this was the form of the vitaminstudied. Supplements of beta- carotene, a natural precursor ofvitamin A, are not a predictable source of the vitamin since eachperson breaks down beta-carotene differently.
  • Make a point of eating a balanced diet, without selecting foodsthat are especially high in vitamin A.
  • Avoid taking high-dose vitamin E supplements.

“One of my biggest concerns is that people will make themistake of thinking that vitamin A supplementation in excess of the15,000 IU recommended will provide even greater benefit,” saidDr. Berson. “We have evidence in fact that supplementation of aregular diet with greater than 15,000 IU of vitamin A does not providegreater benefit. Moreover, a daily vitamin A intake exceeding 25,000IU over the long term can be toxic in adults and may cause sideeffects such as liver disease.

“Our interpretation of the study results is that the course ofthe common forms of retinitis pigmentosa is slower on average amongadult patients on a regular diet who take a daily, 15,000 IU vitamin Asupplement in the palmitate form compared with the course of thosepatients not on this supplement,” he said.

Because the study involved adults between the ages of 18 and 49, noformal recommendations can be made for patients under the age of 18.

Dr. Berson warned that women with RP should not take 15,000 IUvitamin A supplements during pregnancy because high doses of vitamin Ahave been linked to birth defects.

A single capsule containing 15,000 IU of vitamin A in the palmitateform will soon be available commercially. For further information onits availability, Contact the RP Foundation Fighting Blindness*toll-free at 1-800-683-5555.

Background Information on the Study

This study was a prospective, double-masked clinical trial (neitherthe patient nor the clinician knew to which treatment group thepatient had been assigned). It was designed to assess theeffectiveness of vitamin A and/or E supplements in halting or slowingthe progression of RP.

An independent Data Safety and Monitoring Committee provided adviceto the investigators and monitored the accumulating data on a regularbasis for evidence of harm or benefit to study participants.

A total of 601 RP patients from across the United States and Canadawere enrolled in the study. All were in good general health, betweenthe ages of 18 and 49, and entered the study with different initiallevels of retinal function. Following an examination, participantswere assigned randomly to one of four treatment groups:

  • 15,000 IU vitamin A + 3 IU vitamin E
  • 75 IU vitamin A + 3 IU vitamin E
  • 15,000 IU vitamin A + 400 IU vitamin E
  • 75 IU vitamin A + 400 IU vitamin E

Thereafter, the researchers examined each patient annually, with amean follow-up time of 5.2 years. The electroretinogram (ERG) was usedas the study’s primary outcome measure. The ERG is a light-evokedelectrical response from the retina that can be accurately measuredusing a special Contact lens, much like an electrocardiogram measurescoronary function. An ERG provides an objective measure of a person’sretinal function. The scientists also used visual fields and visualacuity as additional measures of visual function.

This clinical trial was conducted at the Berman-Gund Laboratory forthe Study of Retinal Degenerations at the Massachusetts Eye and EarInfirmary in Boston, Massachusetts. It was supported by the NationalEye Institute and, in part, by the RP Foundation Fighting Blindness*in Baltimore, Maryland. The National Eye Institute, a part of theNational Institutes of Health, is the Federal government’s lead agencyfor the conduct and support of research on the human visual system inhealth and disease.

*RP Foundation Fighting Blindness is now called the FoundationFighting Blindness.

# # #

Citations

  • Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. A Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa. Arch Ophthalmol. 1993 Jun. PubMed

June 1993

  • NEI Home
  • Contact Us
  • A-Z Site Map
  • NEI on Social Media
  • Information in Spanish (Información en español)
  • Website, Social Media Policies and Other Important Links
  • NEI Employee Emergency Information
  • NEI Intranet (Employees Only)
  • Department of Health and Human Services
  • The National Institutes of Health
  • USA.gov

*PDF files require the free Adobe® Reader® software for viewing.

Technical questions about this website can be addressed to the NEI Website Manager.